Evidence map›Paper›PMID 37216350›Full record

ArticlePloS one2023

Deep learning generates custom-made logistic regression models for explaining how breast cancer subtypes are classified.

Takuma Shibahara, Chisa Wada, Yasuho Yamashita, Kazuhiro Fujita, Masamichi Sato, Junichi Kuwata, Atsushi Okamoto, Yoshimasa Ono

Abstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Takuma ShibaharaResearch and Development Group, Hitachi Limited, Tokyo, Japan.ORCID 0000-0003-1559-9805
Chisa WadaBioinformatics Group, Translational Research Department, Daiichi Sankyo RD Novare Coporation, Limited, Tokyo, Japan.
Yasuho YamashitaResearch and Development Group, Hitachi Limited, Tokyo, Japan.
Kazuhiro FujitaBioinformatics Group, Translational Research Department, Daiichi Sankyo RD Novare Coporation, Limited, Tokyo, Japan.
Masamichi SatoBioinformatics Group, Translational Research Department, Daiichi Sankyo RD Novare Coporation, Limited, Tokyo, Japan.
Junichi KuwataResearch and Development Group, Hitachi Limited, Tokyo, Japan.
Atsushi OkamotoBioinformatics Group, Translational Research Department, Daiichi Sankyo RD Novare Coporation, Limited, Tokyo, Japan.
Yoshimasa OnoTranslational Research Department, Daiichi Sankyo RD Novare Coporation, Limited, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Differentiating the intrinsic subtypes of breast cancer is crucial for deciding the best treatment strategy. Deep learning can predict the subtypes from genetic information more accurately than conventional statistical methods, but to date, deep learning has not been directly utilized to examine which genes are associated with which subtypes. To clarify the mechanisms embedded in the intrinsic subtypes, we developed an explainable deep learning model called a point-wise linear (PWL) model that generates a custom-made logistic regression for each patient. Logistic regression, which is familiar to both physicians and medical informatics researchers, allows us to analyze the importance of the feature variables, and the PWL model harnesses these practical abilities of logistic regression. In this study, we show that analyzing breast cancer subtypes is clinically beneficial for patients and one of the best ways to validate the capability of the PWL model. First, we trained the PWL model with RNA-seq data to predict PAM50 intrinsic subtypes and applied it to the 41/50 genes of PAM50 through the subtype prediction task. Second, we developed a deep enrichment analysis method to reveal the relationships between the PAM50 subtypes and the copy numbers of breast cancer. Our findings showed that the PWL model utilized genes relevant to the cell cycle-related pathways. These preliminary successes in breast cancer subtype analysis demonstrate the potential of our analysis strategy to clarify the mechanisms underlying breast cancer and improve overall clinical outcomes.

Indexed as

Breast NeoplasmsDeep LearningBiomarkers, TumorFemaleGene Expression ProfilingHumansLogistic ModelsPrognosisBiomarkers, Tumor

Identifiers

PMID37216350
PMCPMC10202302

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.